Condition: Acute Myeloid Leukemia · Sponsor: Ryvu Therapeutics SA
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2
This description comes directly from the study's public registry record.
Head of Clinical Operations · +48-538-898-766 · clinicaltrials@ryvu.com
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Universitaire Grenoble Alpes | Grenoble, France | Recruiting |
| Centre Hospitalier Le Mans | Le Mans, France | Recruiting |
| Centre Hospitalier Universitaire De Lille | Lille, France | Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Recruiting |
| Centre Hospitalier Universitaire De Nice | Nice, France | Recruiting |
| Centre Hospitalier Universitaire De Nimes | Nîmes, France | Recruiting |
| Assistance Publique Hopitaux De Paris | Paris, France | Recruiting |
| Centre Henri Becquerel | Rouen, France | Recruiting |
| Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | Meldola, Forlì-Cesena, Italy | Recruiting |
| Azienda Ospedaliero Universitaria Delle Marche | Ancona, Italy | Recruiting |
| Univerisity of Bologna Policlinico Sant'Orsola | Bologna, Italy | Recruiting |
| Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia | Brescia, Italy | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06191263